What are the best treatments for Primary Hyperoxaluria?

Primary Hyperoxaluria (PH) is a group of rare genetic metabolic disorders characterized by the overproduction of oxalate, leading to recurrent kidney stones and systemic complications. The most effective treatment strategies focus on reducing oxalate production and protecting kidney function through high fluid intake, specific medications, and, in advanced cases, liver or kidney transplantation.

What are the current first-line treatments for Primary Hyperoxaluria?

Management of Primary Hyperoxaluria centers on aggressive hydration to keep urine dilute and prevent crystal formation. First-line pharmacological interventions typically include pyridoxine (Vitamin B6) therapy, which can significantly reduce urinary oxalate levels in a subset of patients with PH type 1 who retain some enzyme activity. Additionally, citrate supplements (such as potassium citrate) are often prescribed to inhibit the crystallization of calcium oxalate within the kidneys.

What are the primary surgical and non-pharmacological interventions?

When Primary Hyperoxaluria progresses to end-stage renal disease (ESRD), renal replacement therapy becomes necessary. Because the metabolic defect in Primary Hyperoxaluria type 1 originates in the liver, a combined liver-kidney transplant is often the gold standard to correct the underlying enzyme deficiency and replace damaged kidneys. Other non-pharmacological measures include:

• Maintaining a high daily fluid intake to ensure constant diuresis.


• Dietary modifications, although these are generally less effective than medical therapy for this condition.


• Regular monitoring of renal function and systemic oxalate deposition (oxalosis) in tissues like bone and heart.

Are there emerging treatments for Primary Hyperoxaluria?

The landscape for Primary Hyperoxaluria treatment has been transformed by RNA interference (RNAi) therapies, such as lumasiran (Oxlumo). This medication specifically targets the liver to reduce the production of the enzyme that leads to oxalate accumulation. Clinical trials have demonstrated that these therapies can dramatically lower urinary oxalate levels, potentially delaying or preventing the need for organ transplantation in many patients with Primary Hyperoxaluria.

Which specialists should be on a care team for Primary Hyperoxaluria?

Managing Primary Hyperoxaluria requires a multidisciplinary team to address its systemic nature. Essential specialists include a nephrologist, a metabolic geneticist, a urologist for stone management, and a transplant surgeon. Dietitians and clinical psychologists are also vital for supporting the long-term adherence to complex medical regimens and the emotional challenges of living with a rare, chronic condition.

Next steps

• Consult a metabolic nephrologist to determine your specific genetic subtype.


• Connect with the Primary Hyperoxaluria community at DiseaseMaps.org to share experiences with others.


• Discuss the latest RNAi therapies with your care team to see if you are a candidate.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your specialized healthcare team for diagnosis and treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Portal for rare diseases and orphan drugs


• Oxalosis & Hyperoxaluria Foundation (OHF)


• OMIM (Online Mendelian Inheritance in Man) database